Praxis Patient Recruitment Campaign Saves 15 Months in Trial
Brentwood, Tenn.-February 5, 2009-Praxis, a company specializing in centralized patient recruitment for clinical research studies, recently provided patient recruitment services to a global pharmaceutical company for a study to test an investigational medication for a mental health indication. The recruitment program saved a combined 15 months for the 2-protocol program and delivered an 891% return on investment for one protocol and 539% return on investment for the second protocol.
Through Praxis’ upfront protocol feasibility analysis and target audience research, a customized & integrated marketing campaign was developed to increase awareness of the study in the communities surrounding the 90 participating clinical research sites. With only 75% of potential sites activating, 97% of total screenings and randomizations came from the Praxis supported sites utilizing the strategic marketing campaign which consisted of direct to patient branded advertising, on-site recruitment materials and electronic/online strategies.
Additionally, a comprehensive retention campaign was launched to encourage study compliance and completion by each subject. This resulted in a 91% retention rate-which is 30% greater than the industry average for phase III studies.
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit www.GoPraxis.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
